دورية أكاديمية
A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge
| العنوان: | A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge |
|---|---|
| المؤلفون: | Jessica J. Harrison, Wilson Nguyen, Mahali S. Morgan, Bing Tang, Gervais Habarugira, Henry de Malmanche, Morgan E. Freney, Naphak Modhiran, Daniel Watterson, Abigail L. Cox, Kexin Yan, Nicholas K. Y. Yuen, Dylan H. Bowman, Peter D. Kirkland, Helle Bielefeldt-Ohmann, Andreas Suhrbier, Roy A. Hall, Daniel J. Rawle, Jody Hobson-Peters |
| المصدر: | npj Vaccines, Vol 9, Iss 1, Pp 1-14 (2024) |
| بيانات النشر: | Nature Portfolio, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract In 2022, a genotype IV (GIV) strain of Japanese encephalitis virus (JEV) caused an unprecedented and widespread outbreak of disease in pigs and humans in Australia. As no veterinary vaccines against JEV are approved in Australia and all current approved human and veterinary vaccines are derived from genotype (G) III JEV strains, we used the recently described insect-specific Binjari virus (BinJV) chimeric flavivirus vaccine technology to produce a JEV GIV vaccine candidate. Herein we describe the production of a chimeric virus displaying the structural prM and E proteins of a JEV GIV isolate obtained from a stillborn piglet (JEVNSW/22) in the genomic backbone of BinJV (BinJ/JEVNSW/22-prME). BinJ/JEVNSW/22-prME was shown to be antigenically indistinguishable from the JEVNSW/22 parental virus by KD analysis and a panel of JEV-reactive monoclonal antibodies in ELISA. BinJ/JEVNSW/22-prME replicated efficiently in C6/36 cells, reaching titres of >107 infectious units/mL - an important attribute for vaccine manufacture. As expected, BinJ/JEVNSW/22-prME failed to replicate in a variety of vertebrate cells lines. When used to immunise mice, the vaccine induced a potent virus neutralising response against JEVNSW/22 and to GII and GIII JEV strains. The BinJ/JEVNSW/22-prME vaccine provided complete protection against lethal challenge with JEVNSW/22, whilst also providing partial protection against viraemia and disease for the related Murray Valley encephalitis virus. Our results demonstrate that BinJ/JEVNSW/22-prME is a promising vaccine candidate against JEV. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2059-0105 |
| Relation: | https://doaj.org/toc/2059-0105 |
| DOI: | 10.1038/s41541-024-00903-2 |
| URL الوصول: | https://doaj.org/article/50e82a1927aa45cd9168982de5cc7e99 |
| رقم الأكسشن: | edsdoj.50e82a1927aa45cd9168982de5cc7e99 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 20590105 |
|---|---|
| DOI: | 10.1038/s41541-024-00903-2 |